Ustekinumab for the treatment of plaque psoriasis: A 6 -year real -life tertiary institution experience

Abstract

Abstract Background: Since the causative mechanism of psoriasis has an immunologic basis, various novel therapeutic agents selectively targeting abnormal immune responses were developed previously. This study aimed to present the 6-year follow-up of results of patients received ustekinumab for plaque psoriasis. Methods: A 6-year real -life data of 80 patients with plaque psoriasis receiving ustekinumab were compiled from the medical archive of our tertiary institution retrospectively and presented. Results: Eighty patients with psoriasis received ustekinumab [28 (35%) females and 52(65%) males, mean age: 50.7 ±14.1 (22-80) years] were included. Overall PASI75 response rate was 72.5% on 16th week, 82.5% on 28th week and 86.25% on 52nd week. The overall PASI90 response rate was 61.25% on 16th week, 73.75% on 28th week and 76.25% on 52nd week Both PASI75 and PASI90 response rates did not significantly differ between naive and non-naive patients. The week of PASI75 and PASI90 achievement did not significantly differ between the patients between naive and non-naive patients, and between males and females. Both PASI75 and PASI90 achievement weeks were not significantly different between the patients with a baseline PASI of under and over 10. No severe side effect was detected. Conclusions: Our 6-year real-life clinical experience we show the effectiveness and safety of ustekinumab in plaque psoriasis even biological naive and non -naive patients.